Help in Fort Bend

This Houston suburb is the newest COVID-19 vaccine hub in the region

Fort Bend is now a COVID-19 vaccine hub. Photo by Matthew T. Carroll/Getty Images

A major Houston suburb is the newest major COVID-19 vaccine hub in the region. Fort Bend County has received an additional 8,000 vaccines, county judge KP George announced on February 9 at a press conference.

That means the county is officially an vaccine hub and will receive regular doses of inoculations, George added. Registration is available at the Fort Bend County website.

During the news conference, George said Fort Bend County had been officially designated as a vaccine hub, meaning the county will now be receiving regular doses of the vaccine.

In keeping with statewide mandates, vaccinations are open to those who are in phases 1A or 1B, although those in the next phases will be eligible at a later date, according to the press conference.

This news comes as the Greater Houston area has seen the emergence of the South African COVID-19 variant, as well as two mutations of the UK strain, as CultureMap previously reported.

Texas Gov. Greg Abbott has also ordered a mega vaccine site in the Houston area that promises to deliver some 5,000 to 6,000 inoculations per day. Houston has also received thousands of new vaccines this week.

Meanwhile, for now, COVID hospitalizations are seeing a downturn, according to reports.

For more information on Fort Bend County vaccinations, visit www.fbchealth.org or call 832-471-1373.

------

This article originally ran on CultureMap.

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News